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Abstract
Background: The association of the xenotropic murine leukemia virus-related virus (XMRV) with prostate cancer continues
to receive heightened attention as studies report discrepant XMRV prevalences ranging from zero up to 23%. It is unclear if
differences in the diagnostic testing, disease severity, geography, or other factors account for the discordant results. We
report here the prevalence of XMRV in a population with well-defined prostate cancers and RNase L polymorphism. We
used broadly reactive PCR and Western blot (WB) assays to detect infection with XMRV and related murine leukemia viruses
(MLV).
Methodology/Principal Findings: We studied specimens from 162 US patients diagnosed with prostate cancer with a
intermediate to advanced stage (Gleason Scores of 5–10; moderate (46%) poorly differentiated tumors (54%)). Prostate
tissue DNA was tested by PCR assays that detect XMRV and MLV variants. To exclude contamination with mouse DNA, we
also designed and used a mouse-specific DNA PCR test. Detailed phylogenetic analysis was used to infer evolutionary
relationships. RNase L typing showed that 9.3% were homozygous (QQ) for the R462Q RNase L mutation, while 45.6% and
45.1% were homozygous or heterozygous, respectively. Serologic testing was performed by a WB test. Three of 162 (1.9%)
prostate tissue DNA were PCR-positive for XMRV and had undetectable mouse DNA. None was homozygous for the QQ
mutation. Plasma from all three persons was negative for viral RNA by RT-PCR. All 162 patients were WB negative.
Phylogenetic analysis inferred a distinct XMRV.
Conclusions and Their Significance: We found a very low prevalence of XMRV in prostate cancer patients. Infection was
confirmed by phylogenetic analysis and absence of contaminating mouse DNA. The finding of undetectable antibodies and
viremia in all three patients may reflect latent infection. Our results do not support an association of XMRV or MLV variants
with prostate cancer.
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Introduction
Prostate cancer is one of the most frequent, slow growing,
noncutaneous malignancies of men in the developing world [1].
For example, it is estimated that over 192,000 men in the US,
mostly of African-American descent, will be diagnosed with
prostate cancer this year [2,3]. Although the natural history of
prostate cancer is currently unknown, multiple etiologies have
been hypothesized, including genetic defects [4,5,6]. In 2006,
using microarray and RT-PCR analysis xenotropic murine
leukemia virus (MLV)-related virus (XMRV) was first identified
in about 40% of familial prostate cancer patients containing the
R462Q mutation in the RNase L gene, a component of the
antiviral innate immunity [7]. MLVs are endogenous gammar-
etroviruses that have integrated into the mouse genome and can
cause cancer, neurologic disease, and immunodeficiency disor-
ders in mice and are classified into three groups based on their
host tropism [8]. Xenotropic MLV (XMLV) replicate only in
non-mouse cells. In contrast, ecotropic MLV (EMLV) replicate
only in mice, while polytropic MLV (PMLV) have a broader
tropism and can replicate in mouse and non-mouse hosts [8].
XMRV shares about 93% and 89% nucleotide identity with
XMLV and PMLV across the genome [7]. Identification of a
possible viral cause of prostate cancer is highly significant because
it could facilitate treatment and prevention of this debilitating
disease.
Additional evidence for XMRV infection of persons with
prostate cancer has been reported in a US study showing a higher
prevalence of XMRV DNA detection by PCR (6%) and viral
proteins by immunohistochemistry (IHC) (23%) in prostate tissues
from 334 prostate cancer patients compared to 101 benign
controls (1.9% by PCR and 3.9% by IHC) [9]. This study also
reported finding XMRV more frequently in patients with a higher
prostate tumor grade suggesting a causal link between virus and
disease. A similar trend was reported in another study that
reported a 22% XMRV prevalence rate in prostate cancer
patients from Texas but found virus in both tumor and non-tumor
tissues [9,10]. XMRV neutralizing antibodies were identified
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19065recently in 11 of 40 (27.5%) US prostate cancer patients and
XMRV sequences were confirmed in five of these 11 persons by
using nested DNA PCR and fluorescence in situ hybridization
(FISH) [11].
In contrast, studies in Europe and two from the US reported
little or no XMRV infection [12,13,14,15,16]. One study of
German prostate cancer patients and one in The Netherlands
found a much lower XMRV prevalence (1/87, 1.2% and 3/
74=4%, respectively) using only RT-PCR and XMRV-specific
primers [12]. A second larger study in Germany using a
combination of DNA and RNA PCR found no evidence of
XMRV infection in 589 patients [14]. In addition, sera from an
additional 146 prostate cancer patients were all negative by testing
with an ELISA incorporating recombinant XMRV envelope (Env)
and Gag proteins and by indirect immunofluorescence assays
expressing XMRV [14]. XMRV was also not found in DNA from
tissues from 161 and 200 prostate cancer patients from two U.S.
populations, respectively [13,15]. The study by Aloia et al. also did
not detect XMRV proteins in tissues from 596 prostatic
adenocarcinomas and 452 benign prostate tissue specimens using
IHC [13].
The reasons for the incongruent XMRV results are not known
but may be related to technical differences in XMRV testing or to
factors related to the patient populations, including disease stage,
genetic factors, or geographical clustering. Similar discordant
results have also been reported recently for XMRV in persons
with the chronic fatigue syndrome (CFS) [17,18,19,20,21,22,23],
including a study by Lo et. al reporting PMLV-like sequences
among US patients with CFS [24]. The majority of the prostate
cancer studies utilized PCR with XMRV-specific primers which
may not be highly sensitive for other MLV-like variants
[7,9,10,11,12,15,16]. In addition, most studies did not perform
serologic testing for antibodies that are hallmarks of retroviral
infections and can, thus, provide additional evidence of infection
that is not tissue-specific.
We report here XMRV testing of a well-characterized cohort of
162 prostate cancer patients from the US by using a combination
of serologic and PCR assays capable of detecting XMRV and
PMLV. We also measured the distribution of the RNase L QQ
mutation to evaluate the association of XMRV with this mutant
allele [7]. We also have used a sensitive PCR test to detect
contamination with murine DNA and exclude false positive PCR
results. Our findings show that XMRV is rare in this patient
population and do not support an association of this virus with
prostate cancer.
Results
Rare XMRV sequences in tumor tissues from prostate
cancer patients
ß-actin sequences were detected by PCR in the DNA extracts
from all prostate tissues confirming their integrity for PCR
testing. DNA from only two (5956 and 6203) of 162 patients
(1.23%) tested positive for XMRV sequences in the initial
screening (Fig. 1, Table 1). Of the 77 DNA specimens that were
additionally tested in triplicate by the pol PCR assay, only one
patient (5935) (1.3%) was found positive. This specimen was
positive in only one of three replicates. Thus, the overall PCR
prevalence was 3/162 or 1.85%. Patient 5956 was positive for
gag and pol sequences in 3/5 and 4/6 repeat tests, respectively,
and env sequences were also detected in 1/3 repeat tests
(Table 2). Specimen 5956 was also positive in all three replicate
pol PCR tests. Only XMRV pol and env sequences were detected
in patient 6203 prostate tissue DNA in 1/4 and 1/1 repeat tests,
respectively. Additional testing of DNA extracted from another
prostate tissue section of 6203 was repeatedly negative, likely
reflecting an uneven distribution of low copy XMRV in this
tissue. DNA from all three patients repeatedly tested negative
for murine mtDNA demonstrating the absence of contaminating
mouse DNAs. To test for viremia we analyzed RNA extracts
from plasma specimens from all three patients. All samples
had undetectable sequences by the qRT-PCR and nRT-PCR
tests.
Identification of XMRV diversity in prostate cancer
patients
Sequence analysis showed that patients 5935, 5956 and 6203
are infected with variant XMRV strains. The 168-bp pol sequences
from all three patients showed 90.5–100% nucleotide identity to
each other, 94–100% to XMRV, 91.7–98.8% to XMLV, 94–
100% to PMLV, and 91–100% to ecotropic MLV (EMLV) in this
short region. 164-bp env sequences from persons 5956 and 6203
were identical to each other and shared the highest nucleotide
identity (94.9–100%) to XMRV and other xenotropic MLV
strains, respectively, [25]. The env sequences from both persons
were highly divergent from EMLVs sharing only about 46%
nucleotide identity. 413-bp gag sequences were only amplified from
the prostate tissue DNA of person 5956 and had about 98%
nucleotide identity to XMRV but was identical to a xenotropic
mERV found on mouse chromosome 8 (GenBank accession #
AC127575).
Figure 1. Identification of XMRV sequences in prostate cancer patients. Representative nested pol PCR results using prostate tumor DNA.
Lanes 1–24, prostate cancer patients, including patients 5956 (lane 8) and 6203 (lane 19); lane 25, negative human PBMC DNA control; lanes 26 and
27, water only controls for primary and nested PCR tests, respectively; lanes 28 and 29, assay sensitivity controls consisting of 10 and 10
3 copies of
XMRV VP62 plasmid DNA diluted in a background of 1 ug of human PBMC DNA, respectively.
doi:10.1371/journal.pone.0019065.g001
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clusters with strong bootstrap support based on viral tropism as
expected, since this region includes a portion of the viral surface
membrane involved in cellular tropism (Fig. 2a). The env sequences
from both patients clustered with XMLV sequences but were
distinct from previously reported XMRV and prototypical PMLV
(Fig. 2a). In contrast, the inferred phylogenetic relationships of pol
sequences from all MLV groups showed that this region does not
cluster by host range (Fig. 2b). The three pol sequences from the
prostate cancer patients formed a well-supported lineage contain-
ing a neuropathogenic Moloney MLV recombinant (strain ts-1-
92b, GenBank accession # AF462057) (Fig. 2b). XMRV pol
sequences from previously reported prostate cancer patients
(coded with VP), except two (VP29 and VP184, kindly provided
by Joe DeRisi), clustered with those from persons with CFS (coded
with WPI) with significant bootstrap support. VP29 and VP184 pol
sequences were identical to each other but 1.2% divergent from
other XMRV and formed a weakly supported cluster containing a
mixture of EMLV and PMLV (Fig. 2b). These results demonstrate
a broader diversity of XMRV in this region than previously seen,
but are consistent with recombination with Moloney MLV as
reported recently [7,25]. VP29, VP79, VP86, VP88, VP90, and
VP184 are prostate cancer patients reported in the Urismann et al.
paper but for which the XMRV pol sequences are not yet available
at GenBank [7]. Newly reported gag and pol sequences found in
human tumor cell line DNA were located outside the regions used
in our study and thus were not included in the analyses [25].
The gag sequence from patient 5956 clustered with XMRV
sequences from a prostate cancer patient (VP88), a xenotropic
mERV found on mouse chromosome 8, and a PMLV sequence
identified in a blood donor (BD-28) by Lo et al. (Fig. 2c) [24]. This
lineage was between clades containing XMRV from prostate
cancer and CFS patients and most PMLVs and the remaining
MLVs found in the Lo et al. study [24]. One prototypical PMLV
(MCF1233) clustered with all EMLVs and two XMRVs,
suggesting it is a recombinant in this region (Fig. 2c).
These phylogenetic results also suggest the short region of env
targeted by our new PCR assay is useful for determining viral
tropism for typing the MLV-related sequences. This information
may be helpful in understanding the origin of the sequences
identified in PCR-positive humans. In contrast, the gag and pol
regions showed less clustering by tropism indicating viral
recombination in these regions. For example, the gag sequences
of prototypical XMLVs (MTCR), EMLVs (AKV, BM5eco), and
PMLVs (MCF1233) clustered together with highly significant
bootstrap support (Fig. 2a).
Nearly identical phylogenetic tree topologies for each gene
region were obtained with both the NJ and ML methods. The
XMRV sequences from both prostate cancer patients were also
distinct from the PMLV sequences amplified from the murine cell
line (RAW) used for preparing WB antigens demonstrating further
that these are not laboratory contaminants (Fig. 2). These results
confirm the presence of XMRV in both patients and demonstrate
that XMRV diversity is greater than currently appreciated.
Table 1. XMRV/MLV infection is rare in prostate cancer
1,2.
RNase L R462Q Genotype XMRV/MLV nPCR
3 Serology
Sample Type Sample Total RR RQ QQ GAG POL WB
Prostate
Tissue DNA
162 74 (45.7) 73 (45.1) 15 (9.3) 1 (0.6) 3 (1.9) -
Plasma 162 - - - - - 0/162 (0)
1Percentages in parentheses.
2Dashes indicate test not performed on these sample types.
3nPCR, nested PCR.
doi:10.1371/journal.pone.0019065.t001
Table 2. Detection of XMRV in three prostate cancer patients
1.
XMRV/MLV nPCR
3 qRT-PCR
4 nRT-PCR
5 Murine PCR
6
Patient ID
Specimen
Type
2
RNase L Q462R
genotype gag pol
7 env pro gag MCOX2
5935 PTT DNA RQ 0/3 1/4 0/3 - - 0/1
Plasma - - - 0/1 0/3 -
5956 PTT DNA RR 3/5 7/9 1/3 - - 0/3
Plasma - - - - 0/2 0/3 -
6203 PTT DNA RQ 0/4 1/4 1/1 - - 0/2
Plasma - - - 0/2 0/3 -
1Dashes indicate test not performed.
2PTT, prostate tumor tissue.
3nPCR, nested PCR; gag, group specific antigen; pol, polymerase; env, envelope.
4qRT-PCR, quantitative RNA PCR; pro, protease gene.
5nRT-PCR, nested RNA PCR.
6Murine PCR, test for detection of specimen contamination with mouse cells or DNA using mitochondrial primers (MCOX2).
7For specimens 5935 and 5956 testing includes results of triplicates and the initial screening. Quantity of DNA for 6203 was insufficient for triplicate testing.
doi:10.1371/journal.pone.0019065.t002
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19065The XMRV sequences presented in the current paper are
available at GenBank with the accession numbers HM003608–
HM003612, and HQ116790. Sequences from other studies with
XMRV-positive prostate cancer patients were not available at
GenBank for inclusion in our analyses [9,11,12,16].
Absence of antibodies in plasma from prostate cancer
patients
All 162 prostate cancer patient plasma samples were found to be
negative for antibodies to XMRV/MLV in the WB test, including
plasma from persons 5935, 5956, and 6203 (Fig. 3). In most
plasma specimens some level of nonspecific reactivity was observed
to the uninfected antigen but without evidence of specific reactivity
to Gag and/or Env proteins in the infected antigen blot (Fig. 3).
RNase L R462Q allelic distribution in the study
population and clinical characteristics of the three
XMRV-infected persons
15 of the 162 persons (9.3%) were determined to be homozygous
(QQ) for the R462Q RNase L mutation, 74 (45.6%) had the
homozygous RR allele, and 73 (45.1%) were heterozygous (RQ) for
the mutation (Table 1).
Patient 5935 is the heterozygous RQ RNase L genotype. He has
a poorly differentiated adenocarcinoma with a Gleason’s score of
6, T2C pathologic stage, PSA level of 4.6 ng/mL. Patient 5956 is
the wild-type homozygous RR RNase L genotype. He had a
poorly differentiated adenocarcinoma with a Gleason’s score of 7,
T3A pathologic stage, a 12.4 ng/mL PSA level. Patient 6203 is the
heterozygous RQ RNase L genotype, and had a moderately
differentiated adenocarcinoma with a Gleason’s score of 6, T2C
pathologic stage, and a 7.1 ng/mL PSA level. Thus, we were
unable to confirm an association of XMRV infection with the
homozygous QQ RNase L allele. Given the low XMRV
prevalence, we did not have the statistical power to determine if
there is an association of XMRV with tumor grade.
Discussion
We used PCR and serologic testing to study the prevalence of
XMRV in 162 well-characterized North American patients with
prostate cancer. We surveyed cancers with intermediate to advanced
stages, and utilized multiple PCR assays, including tests with
conserved primers to allow the detection of diverse XMRV and
MLV-related sequences. Nearlyhalf the specimens were also tested in
triplicate to maximize the detection sensitivity of low-copy sequences.
We used a broadly reactive WB assay to test all patients for
antibodies. Our findings document a very low prevalence (1.9%) of
XMRV sequences in prostate tissue DNA and absence of antibody
positivity in all specimens. Combined these data do not support an
association of XMRV or related MLV with prostate cancer.
The predominantly negative PCR results were observed despite
the use of 1 ug of DNA which is 4–106 higher than the input
DNA used in previous studies that reported XMRV detection
[7,9,14,16]. Likewise, the observed low prevalence of XMRV may
not be explained by a decreased PCR assay sensitivity since we
screened specimens with the same assay used originally by
Urisman et al. [7]. In the three specimens with detectable
sequences, we noted that the copy number was very low as nested
PCR and replicate testing was often needed for detection.
Importantly, in all three specimens we were unable to detect
mouse mtDNA despite the use of a highly sensitive assay, which
suggests that the source of XMRV is unlikely the result of
contamination with mouse DNA. These results are important
since mouse DNA contamination was reported to be the source of
XMRV in a recent study of prostate cancer tissues [26]. The
authors of this study used a PCR assay for the mouse intracisternal
A particle (IAP) which they reported to be more sensitive than a
mouse-specific D-loop mtDNA-based assay [26]. Although DNA
specimens were not available for testing in the IAP test, we have
found that the IAP assay is equally sensitive to our COX2 real-
time mtDNA assay (data not shown), thus further excluding mouse
DNA contamination as a source for our positive PCR results. In
addition, the DNA specimens were prepared at FCCC where only
human biological specimens, and not cell lines, are handled,
reducing further the possibility of murine contamination.
Sequence analysis of the PCR-positive specimens was highly
informative because it confirmed that all three specimens were
XMRV-related. Also, the finding of a viral strain in three prostate
cancer patients that is distinct from the XMRV seen in previous
studies is significant and demonstrates a broader viral diversity
[7,9,14,16]. This would be an expected result consistent with virus
evolution during spread and persistence. The absence of
antibodies and plasma viremia in these three patients is
noteworthy because it may reflect sequestered or latent infections.
Loss of antibody during a latent infection, while atypical of most
retroviral infections, has been described previously for natural
infection of macaques with simian type D retroviruses (SRV) [27].
SRV in macaques is associated with outbreaks of severe immune
deficiency in primate colonies and latent SRV infection in these
antibody negative animals is confirmed with greater sensitivity
using PCR analysis [27]. Our results are also consistent with those
seen recently in macaques experimentally infected with XMRV in
which tissues at necropsy are PCR-positive but viremia and
detection of provirus in PBMCs disappear quickly, followed by loss
of antibody detection [28,29]. Although one study reported the
detection of XMRV neutralizing antibody in 11 patients with
prostate cancer, these data were not confirmed by more sensitive
methods such as WB, or by PCR testing in all cases, and thus may
represent nonspecific reactivity [11,17]. Longitudinal studies may
better define host responses to XMRV infection.
Figure 2. Identification of variant XMRV in prostate cancer patients using phylogenetic analysis. A. envelope (env), B. polymerase (pol),
and C. gag. Stability of the tree topology was tested using 1000 bootstrap replicates in both neighbor joining (NJ) and maximum likelihood (ML)
methods. Bootstrap values .60 are shown at major nodes (NJ/ML). New sequences from the current study are boxed. Accession numbers for
prototypical MLV sequences available at GenBank are XMRV VP35=DQ241301, XMRV VP62=DQ399707, XMRV VP42=DQ241302, XMRV WPI-
1106=GQ497344, XMRV WPI-1178=GC497343, XMRV PCA1–PCA17=GU812341–GU812357, MLV DG-75=AF221065, MLV MTCR=NC_001702, MLV
AKV=J01998, MLV BM5eco=AY252102.1, Moloney MLV=J02255, Moloney neuropthogenic MLV variant ts1-92b=AF462057, Rauscher
MLV=NC_001819, Friend MLV=X02794, mERV Chr 7=AC167978, mERV Chr 7=AC127565, mERV Chr 8=AC127575, mERV Chr 12=AC153658,
mERV Chr 9=AC121813, mERV Chr 4=AL627077, mERV Chr 1=AC083892), XMLV A2780=FR670594, XMLV BHY=FR670595, XMLV
Daudi=FR670596, XMLV EKVX=FR670597, XMLV IMR-5=FR670598, XMLV MUTZ-1=FR670599, XMLV S-117=FR670600, XMLV TYK-nu=FR670601.
Sequences denoted RAW are from the polytropic MLV isolated in HeLa cells used to develop the in-house WB test. Sequences coded as XMRV VP and
PCA and WPI are from prostate cancer and CFS patients, respectively. Additional prostate cancer patient VP gag and pol sequences were kindly
provided by Drs. Robert Silverman and Joe Derisi. Viral tropism, as determined by analysis of env sequences, is indicated by blue (xenotropic), purple
(polytropic), and yellow (ecotropic) spheres.
doi:10.1371/journal.pone.0019065.g002
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RNase Lallele.However,nonewereXMRV-positive,whichcontrasts
with the original findings by Urismann et al. [7]. The XMRV-infected
persons in our study had either the homozygous wild-type (RR) or
heterozygous (RQ) RNase L R462Q alleles. Our results are consistent
with other US and European studies which also identified higher
frequencies of the homozygous QQ mutant allele in XMRV-negative
persons [9,10,16]. Combined, these results suggest that XMRV
infection is not associated with this allelic form of RNase L.
Although our data do not support an association of prostate
cancer with XMRV, it is important to understand whether
XMRV has any causal role in prostate cancer when it is
infrequently detected. In general, gammaretroviruses like XMRV
induce malignant transformation by insertional mutagenesis, so
that malignant cells in a tumor are all clonally infected. This
mechanism of carcinogenesis has been found in animals as well as
in children exposed to MLV-derived vectors in gene-therapy trials
[30,31]. Therefore, the low-frequency of XMRV-infected cells
found in all three patients are inconsistent with a direct role of
XMRV in the prostate carcinogenesis in these patients. Previously,
a human prostate cancer cell line, 22Rv1, has been shown to
express high levels of XMRV, a finding that supports a role of
XMRV in prostate cancer tumorigenesis [32]. However, it was
reported recently that the XMRV expressed by 22Rv1 may not be
of human origin, but most likely arose via recombination of two
overlapping XMRV-like genomes during passage of the prostate
tumor in inbred mice (T. Paprotka et al. 18
th Conference on
Retroviruses and Opportunistic Infections). Furthermore, others
have shown that XMRV integration sites cloned from prostate
tissues of two of nine patients may have been the result of
contamination with DNA from experimentally infected DU145
cells [33], while other XMRV integration sites are not near tumor
suppressor genes or proto-oncogenes [34]. Combined, these results
raise questions about the role of XRMV in prostate cancer.
Nonetheless, more work is needed to better understand the
prevalence of XMRV and MLVs in humans and their role in
human disease.
Materials and Methods
Study population
Anonymous, archived plasma and prostate tissue were available
from 162 U.S. prostate cancer patients collected by the Fox Chase
Cancer Center (FCCC) Biosample Repository Core Facility
between 1997 and 2004. Whole blood specimens were collected
at the time of pre-surgical testing or on the day of surgery prior to
anesthesia from consenting cancer patients as part of a study
approved by the FCCC Human Subjects Committee. Written
informed consent was obtained from all participants. The FCCC
Human Subjects Ethics Committee approved collection, storage,
and future testing of the specimens collected from all consenting
study participants. A non-research determination was approved
for testing of the anonymized samples at CDC for XMRV and
related viruses. The age at diagnosis of the 162 participants ranged
from 36 to 71 years old with an average and median of 57 years.
86% were Caucasian, 12% African American, and 1% were
Asian, not recorded, or other. The average and median serum
prostate-specific antigen (PSA) levels were 7.22 ng/mL and
5.5 ng/mL, respectively. The tumor grade for 75 of 162 (46%)
of the participants was moderately differentiated, while 54% had
poorly differentiated tumors. Using the Gleason system, 42% of
the study population had grade 5–6 cancer, 40% had grade 7, and
18% had high grade adenocarcinoma (Gleason’s score 8–10).
Pathologic staging classified the prostate tumors as T1C (0.6%),
T2A (9.3%), T2B (3.1%), T2C (61.7%), T3A (17.9%), T3B (5.6%),
and T4 (1.8%).
Specimen preparation
Plasma was aliquoted and stored at 280uC within 4 hours of
blood collection. Plasma samples were aliquoted again at the CDC
after thawing for serologic testing; the remaining aliquots were
frozen at 280uC. DNA samples were prepared by phenol-
chloroform extraction of prostate tissues at FCCC using standard
Figure 3. Absence of antibodies to XMRV and MLV in prostate
cancer patients. Molecular weight markers (kD) are provided on the
left of the WBs in the upper panels. Expected sizes of viral Gag (p30,
capsid (CA)), pr65, and Envelope (Env, gp69/71) proteins are provided in
each WB in the upper panels. Representative WB results for eleven
prostate cancer patients, including patients 5956 and 6203 (indicated
with asterisks). Determination of MLV specific reactivity is determined
by comparison of seroreactivity to xenotropic MLV-infected HeLa
antigens and uninfected HeLa antigens in upper and lower panels,
respectively. Ra, Rauscher MLV whole virus goat polyclonal antisera; Fr,
Friend MLV Envelope (gp69/71) goat polyclonal antisera; pre-immune,
goat sera prior to immunization.
doi:10.1371/journal.pone.0019065.g003
Rare XMRV Infection in Prostate Cancer
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19065procedures. Only human tissues are processed at FCCC. For
selected samples the QIAamp DNA minikit (Qiagen, Carlsbad,
CA) was used at the CDC. For plasma RT-PCR testing a volume
of 0.5–1.0 ml was ultracentrifuged at 45,000 rpm to concentrate
virus. 360 ul to 860 ul plasma supernatant was carefully removed
and the pellet was resuspended in 140 ul of centrifuged plasma
remaining in the tube and then RNA was extracted using the
QIAamp Viral RNA minikit (Qiagen, Valencia, CA). Nucleic acid
concentrations were determined by spectrophotometry using the
Nanodrop instrument (Thermo Scientific, Wilmington, DE).
Integrity of the DNA and RNA specimens was determined using
ß-actin or GAPDH PCR, respectively, as described [35,36]. All
specimen preparation, tissue culture, and PCR testing was done in
physically isolated rooms to prevent contamination.
Molecular detection of XMRV
To detect XMRV and other MLV variants we used separate
PCR assays with primers specific for the detection of XMRV, or
conserved primers for the generic detection of MLV and XMRV,
as previously described [21]. DNA specimens were screened using
two nested PCR assays. The first assay uses the PCR primers
GAGOF, GAGOR, GAGIF, and GAGIR employed by Urismann
et al. and by Lombardi et al. to detect 413-bp XMRV gag sequences
in prostate cancer patients and in persons with CFS, respectively
[7,18]. The second PCR assay generically detects MLV and
XMRV polymerase (pol) sequences about 216-bp in length using
the primers XPOLOF, XPOLOR, XPOLIF, and XPOLOR [21].
Both the gag and pol PCR tests can detect 10 copies of XMRV
plasmid DNA diluted in a background of 1 ug of human DNA
[21]. Specimens testing positive for either gag or pol sequences were
re-tested with both assays and were also tested with a third nested
PCR test for XMRV envelope (env) sequences that is also generic
for XMRV/MLV. The external XENVOF (59 GGG GAT CTT
GGT GAG GGC AGG AGC 39) and XENVOR (59 CAG AGA
GAA CAG GGT CAC CGG GTC 39) and internal primers
XENVIF (59 AGG GCT ACT GTG GCA AAT GGG GAT 39)
and XENVIR (59 CCT TTT ACC CGC GTC AGT GAA TTC
39) amplify a 215-bp env sequence. In addition, a subset of
specimens (n=77) for which sufficient DNA was available were
tested in triplicate using the nested pol PCR assay to improve
detection of low copy XMRV/MLV.
PCR was performed using 1 ug of prostate tissue DNA in a
100 ul reaction volume using standard conditions of 94uC for
30 sec, 50uC for 30 sec, and 72uC for 45 sec for 40 cycles on an
ABI 9700 thermalcycler (Foster City, CA). PCR products were
visualized by electrophoresis in an ethidium bromide-stained 1.8%
agarose gel. To increase the sensitivity and specificity of the assays,
amplified gag, pol, and env sequences were confirmed by Southern
blot analysis using the biotinylated oligoprobes XGAGP2 (59 ACC
TTG CAG CAC TGG GGA GAT GTC 39), XPOLP (59 TTG
ATG AGG CAC TGC ACA GAG ACC 39), and XENVP (59
TGG GCT CCG GTA GCA TCC AGG GTG 39) and
chemiluminescence detection. Like the XMRV gag and pol PCR
assays [21], the new XMRV env PCR test was also capable of
detecting 10 copies of XMRV plasmid in a background of 1 ug
human DNA (30/32, 93.8%). We did not detect any XMRV/
MLV sequences in PBMC DNA from 41 US blood donors using
each of the three nested PCR tests [21].
Quantitative XMRV RNA RT-PCR
Plasma samples from persons with positive XMRV PCR results
in the prostate tissue DNA were tested further for viral RNA using
two RT-PCR tests. The first assay, referred to as qpro uses MLV/
XMRV generic protease (pro) Taqman primers Pro-UNV-F1 (59
CCT GAA CCC AGG ATA ACC CT 39) and Pro-UNV-R1 (59
GTG GTC CAG CGA TAC CGC T 39) and probes Pro-UNV-
P1C (FAM59 AGA TAC TGG GGC CCA ACA CTC CGT
GCT GAC 39BHQ1) and Pro-UNV-PR1 (FAM59 CCT CCA
GTA GCC CCT TGG ACC CAG GC 39BHQ1). The second
assay is the nested GAG RT-PCR test used by Urismann et al. and
Lombardi et al. using the primers GAGOF, GAGOR, GAGIF,
and GAGIR to detect XMRV RNA sequences in prostate cancer
patients and persons with CFS [7,18], respectively. For the
Taqman RT-PCR test, 10 ul of RNA extracted from 50 ul plasma
equivalents, 900 nM of primers and 250 nM of probes were used
in a one step RT-PCR reaction mixture at 45uC for 20 min, 95uC
for 10 min, followed by 55 cycles of 95uC for 30 sec, 52uC for
30 sec and 62uC for 30 sec. A plasmid containing the full-length
genome of XMRV (VP62) and RNA extracted from tissue culture
supernatants from the XMRV(VP62)-infected DU145 cell line
(C7) (both kindly provided by Robert Silverman) were used as
positive controls for the assay and for generating the standard
curve for viral quantification [7]. The qRT-PCR pro assay has a
sensitivity of 10 copies of XMRV protease RNA sequences per
reaction in replicate dilutions (40/40, 100%) and a linear range
from 10
1 to 10
8 copies. Plasma from 32 US human blood donors
and 32 HIV-1-infected persons tested negative by this assay.
For the nested gag RT-PCR tests, cDNA was synthesized with
the XMRV-specific reverse primer GAG OR by using iScript
Select cDNA Synthesis Kit (Bio-Rad, Hercules, CA) in a 20 ul
reaction following the manufacturer’s instructions. Briefly, 10 ul
RNA representing extract from 126 ul plasma was mixed with
10 uM GAGOR, 2 ul GSP enhancer solution and Nuclease-free
water in a 15 ul reaction volume. Following incubation at 65uC for
5 minutes and cooling to 4uC, 4 ul of 56 iScript Select reaction
mix and 1 ul reverse transcriptase were added and incubated at
42uC for 1 hr. The reaction was stopped by heating to 85uC for
5 minutes. For first round PCR, 10 ul of the RT product was
mixed with 0.2 uM of the external primers GAG OF and GAG
OR, 2.5 mM of each dNTP, 2.5 mM MgCl2 using the Expand
High Fidelity PCR System (Roche, Indianapolis, IN) and 5 ul 106
PCR buffer in a 50 ul reaction volume for 35 cycles at 94uC for
30 sec, 52uC for 30 sec, and 72uC for 45 sec. For nested PCR,
0.2 uM of the internal primers GAG IF and GAG IR in first
round PCR reaction and run for 40 cycles with annealing
temperature increased to 54uC. Both primary and nested PCR
products were electrophoresed on 1.8% agarose gels and specific
amplicons were detected by Southern blot as previously described.
The nested gag RT-PCR assay had a sensitivity between 25 and
100 copies per reaction in replicate testing of XMRV RNA 92.5%
(37/40) and 97.5% (39/40), respectively, but could also detect 5
copies in 50% (20/40) of the replicates. Plasma from 40 HIV-1
infected persons were all negative by this assay. 32 of these samples
were negative by the pro qRT-PCR test.
Quantitative PCR for murine mitochondrial DNA (mtDNA)
cytochrome oxidase subunit 2 (COX2) sequences
Contamination of specimens with mouse DNA will produce a
false positive PCR result since mouse DNA contains endogenous
MLV sequences that amplify by the diagnostic XMRV/MLV
PCR assays. Thus, to distinguish true infection from specimen
contamination with murine DNA, all specimens testing positive for
XMRV/MLV sequences were also tested for murine mtDNA
COX2 sequences using a newly developed PCR assay. The
primers MCOX2F2 (59 TTC TAC CAG CTG TAA TCC TTA
39) and MCOX2R1 (59 GTT TTA GGT CGT TTG TTG GGA
T3 9) and probes MCOX2PR1 (59 FAM-CGT AGC TTC AGT
ATC ATT GGT GCC CTA TGG T-BHQ 39) and MCOX2P1
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39) were used in a two-step thermocycling of 95uC for 30 sec and
62u C 30 sec for 55 cycles on an iQ5 instrument (Bio-Rad,
Hercules, CA). Dilutions of a plasmid containing murine COX2
sequences that was generated by PCR with the MCOX2F2 and
MCOX2R1 of the murine macrophage cell line RAW264.7
(ATCC, Manassas, VI) was used as the assay standard. 0.5 ug–
1 ug of prostate tissue DNA was tested using the MCOX2
primers. This assay was evaluated on PBMC DNA from 117 US
blood donors and all samples tested negative, demonstrating 100%
specificity of the assay. This test has a 90% and 100% sensitivity of
detecting five and 10 copies of murine MCOX2 sequences in a
background of 1 ug of human DNA, respectively. We were also
able to detect 100–1,000 copies/cell of mtDNA sequences in the
Raw264.7 mouse cell line which is equivalent to detecting a single
mouse cell, assuming there are at least 1,000–10,000 mitochondria
per cell.
Phylogenetic analysis
PCR products were purified with QiaQuick PCR or gel
purification kits (Qiagen, Valencia, CA) and were directly
sequenced on both strands by using ABI Prism BigDye terminator
kits and an ABI 3130xl sequencer (Foster City, CA). Sequences
were aligned using Clustal W in the MEGA v 4.1 program [37].
Following manual editing and removal of indels, phylogenetic
relationships were inferred using the neighbor joining (NJ) method
implemented in MEGA v4.1 [37]. MLV phylogenies were also
inferred using the program PhyML that implements the fast
maximum likelihood (ML) method [38]. Support for the
branching order was evaluated using 1,000 nonparametric
bootstrap replicates.
XMRV Western blot (WB)
A PMLV-infected HeLa cell line was used as antigen in the WB
test as previously described in detail [21]. Briefly, PMLV-infected
and -uninfected HeLa crude cell lysates were prepared as
previously described [21,39]. Plasma or serum samples were
diluted 1:50 and reacted separately to 150 ug of infected and
uninfected cell lysates after protein separation through 4–12%
polyacrylamide gels and then transfered to nytran membranes, as
previously described [21,39,40]. Seroreactivity in human speci-
mens was detected using peroxidase-conjugated protein A/G
(Pierce, Rockford, IL) and chemiluminescence (Amersham,
Uppsala, Sweden) [21,39,40]. Specimens were tested in parallel
against control antigens from uninfected HeLa cells. Seroreactivity
to bands in the WB blots from the infected antigens was compared
to those in uninfected antigens to exclude nonspecific reactivity.
1:500 dilutions of goat polyclonal antibodies to MLV whole
virus and gp69/71Env (ATCC, Manassas, VI; VR-1537 and VR-
1521, respectively) and a 1:50 dilution of pre-immune goat sera
were used as positive and negative controls, respectively, when
testing of the human specimens. These two antisera have been
shown to have high titers to MLV Gag (1:32,000) and Env
proteins (1:8,000) in our WB assay, respectively [21]. In addition,
using this antigen high titers to Gag and Env proteins (1:64,000)
were seen using a rabbit anti-XMRV polyclonal sera and the rat
anti-spleen focus forming virus (7C10) monoclonal antibody
(1:32,000) that were previously used to detect XMRV protein
expression and antibodies in prostate cancer and CFS patients,
respectively [9,18,21]. Thus, samples were examined for serore-
activity to bands corresponding to Gag (p15, p30, pr68/80) and/
or Env (gp69/71, p15E) proteins present in only the infected
antigen and not the uninfected antigen. An absence of background
reactivity in human samples was demonstrated previously using
sera from 121 HIV and HTLV negative anonymous US blood
donors collected in 1998, 13 HTLV-positive, 7 HIV-1-positive, six
HIV-1/HIV-2 dual positive plasma, and pre-immune goat sera
from ATCC [21].
RNase L single nucleotide polymorphism (SNP)
genotyping
DNA concentrations were first measured using the TaqMan
RNase P detection kit (Applied Biosystems, Inc., Foster City, CA)
following the manufacturer’s instructions. 20 ng of DNA was used
in the TaqMan RNase L Q462R SNP Detection Kit
(C____935391_1_) using an ABI 7900HT Fast Real-time PCR
instrument (Applied Biosystems, Inc., Foster City, CA) and
conditions recommended by the manufacturer to determine the
prevalence of wild type and mutant Q462R alleles in our study
population. 20 ng of DNA in a 25 ul reaction volume was used to
determine the SNP genotype. Genomic DNA from cell lines with
known RNase L R462Q alleles were controls for the SNP assay
(Jurkat, QQ; Raji, RR; MCF-7, RQ).
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